Skip to main content Help with accessibility Skip to main navigation

November 2023 updates to the website

The website has now been updated following November's LSCMMG

The following guidelines have been added/updated:

Lipid management pathway - Update to follow

The following medicines have been updated following the Commissioning Resource Group (CRG) meeting:

Bempedoic acid (without ezetimibe) - Treatment of primary hypercholesterolaemia or mixed dyslipidaemia

Tamoxifen - For treating premenopausal women at high risk of breast cancer unless they have a past history or may be at increased risk of thromboembolic disease or endometrial cancer.

Omega 3-acid-ethyl esters - For preterm birth risk reduction

Tacrolimus - For prophylaxis of graft rejection

The following Items will be updated and added to the website following the next Commissioning Resource Group (CRG) Meeting:

Ranolazine - As adjunctive therapy in the treatment of stable angina in patients inadequately controlled or intolerant of first-line antianginal therapies

Bimekizumab - active psoriatic arthritis (NICE TA916)

Bimekizumab - axial spondyloarthritis (NICE TA918)

Rimegepant - treating migraine (NICE TA919)

Tofacitinib - active ankylosing spondylitis (NICE TA920)

Mirikizumab - moderately to severely active ulcerative colitis (NICE TA925)

Baricitinib - severe alopecia areata (NICE TA926)